MicroRNA-based methods and assays for osteosarcoma
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 26, 2016
Grant Date -
Aug 28, 2014
app pub date -
Sep 7, 2012
filing date -
Sep 7, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully